Literature DB >> 17005798

Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.

E Dannaoui1,2, D Garcia-Hermoso2, J M Naccache3, I Meneau4, D Sanglard4, C Bouges-Michel5, D Valeyre3, O Lortholary6,2.   

Abstract

The case is reported of a patient with cavitary sarcoidosis complicated by an aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus, who was treated with voriconazole. The authors suggest that susceptibility testing of A. fumigatus strains is of value during long-term therapy with itraconazole, and that voriconazole may be a good option for treatment of patients infected with itraconazole-resistant strains of A. fumigatus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005798     DOI: 10.1099/jmm.0.46639-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: can MIC values be obtained at 24 hours?

Authors:  Juan Luis Rodriguez-Tudela; Laura Alcazar-Fuoli; Ana Alastruey-Izquierdo; Araceli Monzon; Emilia Mellado; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

2.  Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Authors:  M A Pfaller; D J Diekema; M A Ghannoum; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; A Espinel-Ingroff; C L Fowler; E M Johnson; C C Knapp; M R Motyl; L Ostrosky-Zeichner; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

3.  Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.

Authors:  Juan Luis Rodriguez-Tudela; Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Araceli Monzon; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

4.  Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Authors:  Eleftheria Mavridou; Roger J M Brüggemann; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

5.  Development and validation of a microsphere-based Luminex assay for rapid identification of clinically relevant aspergilli.

Authors:  Kizee A Etienne; Rui Kano; S Arunmozhi Balajee
Journal:  J Clin Microbiol       Date:  2009-02-25       Impact factor: 5.948

Review 6.  Regulation of Sterol Biosynthesis in the Human Fungal Pathogen Aspergillus fumigatus: Opportunities for Therapeutic Development.

Authors:  Sourabh Dhingra; Robert A Cramer
Journal:  Front Microbiol       Date:  2017-02-01       Impact factor: 5.640

7.  In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.

Authors:  Lea Gregson; Joanne Goodwin; Adam Johnson; Laura McEntee; Caroline B Moore; Malcolm Richardson; William W Hope; Susan J Howard
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.